Table 4

Determination of CYP Clint of individual human CYPs to oxidative metabolism for marker substrates

CompoundCLint
CYP1A2CYP2C9CYP2C19CYP2D6CYP3A4
μl · min−1pmol−1
TolbutamideN.D.4-a 0.0144-b 0.03  ± 0.01N.D.N.D.
DiazepamN.D.N.D.0.17  ± 0.05N.D.N.D.
MetoprololN.D.N.D.N.D.1.03  ± 0.07N.D.
IbuprofenN.D.0.29 ± 0.090.17  ± 0.01N.D.N.D.
Propranolol0.34 ± 0.03N.D.0.66  ± 0.065.07  ± 2.80N.D.
DextromethorphanN.D.N.D.0.16  ± 0.101.97  ± 0.24N.D.
OmeprazoleN.D.N.D.6.95  ± 1.93N.D.0.44  ± 0.06
DiltiazemN.D.N.D.0.30  ± 0.04N.D.0.58  ± 0.04
TestosteroneN.D.N.D.N.D.N.D.0.42  ± 0.03
VerapamilN.D.N.D.N.D.N.D.1.19  ± 0.12
  • 4-a  N.D., not detectable (<0.02 μl · min−1 · pmol−1).

  • 4-b  Determined fromVmax/Km. Mean ± S.D. forn = 3 separate experiments.